Miscarriage risk from amniocentesis performed for abnormal maternal serum screening.
OBJECTIVE
The purpose of this study was to evaluate miscarriage after mid-trimester amniocentesis for abnormal maternal serum screening.


METHODS
An analysis of summary data from the California State maternal serum screening program on 32,050 women with an abnormal serum screen, a singleton fetus, and normal ultrasound was performed. Miscarriage before 24 weeks, days until miscarriage, gestational age at miscarriage, and maternal factors were compared. The power of this study could detect a 50% increase in miscarriage.


RESULTS
The miscarriage rate with amniocentesis, 0.46% (69/15,005), was no different than without, 0.53% (90/17,045), P = .38. There was no difference in maternal age, serum biochemical factors, gestational age at miscarriage (21.1 weeks for both groups), or days until miscarriage (23 after amniocentesis and 20.4 without). Log-rank test revealed no difference for gestational age at miscarriage (P = .61) or number of days until miscarriage (P = .40).


CONCLUSIONS
The rate and timing of miscarriage was similar with or without amniocentesis in California women with abnormal maternal serum screening.
Towner
Dena
D
Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of California Davis, Sacramento, CA, USA.
Currier
Robert J
RJ
Lorey
Fred W
FW
Cunningham
George C
GC
Greve
Linda C
LC
D000022:Abortion, Spontaneous / Q000453:epidemiology*; D000649:Amniocentesis / Q000009:adverse effects*; D002140:California / Q000453:epidemiology; D006063:Chorionic Gonadotropin / Q000097:blood; D004964:Estriol / Q000097:blood; D005260:Female; D005865:Gestational Age; D006801:Humans; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D011296:Prenatal Diagnosis; D012306:Risk; D000509:alpha-Fetoproteins / Q000032:analysis
D006063:Chorionic Gonadotropin; D000509:alpha-Fetoproteins; D004964:Estriol